RT Journal Article
SR Electronic
T1 MODELLING PRESYMPTOMATIC INFECTIOUSNESS IN COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.01.20224014
DO 10.1101/2020.11.01.20224014
A1 Russell Cheng
A1 Christopher Dye
A1 John Dagpunar
A1 Brian Williams
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.11.01.20224014.abstract
AB This paper considers SEPIR, the extension of an existing parametric SEIR continuous simulation compartment model. Both models can be fitted to real data as they include parameters that can simply be estimated from the data. However SEPIR deploys an additional presymptomatic (also called asymptomatic) infectious stage that is not included in SEIR but which is known to exist in COVID-19. This stage is also parametrised and so can be fitted to data. Both SEPIR and the existing SEIR model assume a homogeneous mixing population, an idealisation that is unrealistic in practice when dynamically varying control strategies are deployed against virus. This means that if either model is to represent more than just a single period in the behaviour of the epidemic, then the parameters of the model will have to be time dependent. This issue is also discussed in this paper.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Swiss data, ( 109 days of new cases and deaths starting from 15 Feb 2020) referred to in the article is publically available online. https://ourworldindata.org/coronavirus-source-data